BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 23, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/20 cls
Amgen Inc. (NASDAQ:AMGN) Baird Christopher Raymond Price target Market outperform 3% $69.57
Raymond raised his target to $75 from $67 after "very positive" feedback from a November survey of 98 oncologists indicated that his estimates for denosumab were too low. The human mAb targeting receptor activator of NF-kappa B ligand (RANKL) is approved as Prolia in the EU and U.S. to treat osteoporosis in postmenopausal women and in the EU to treat bone loss associated with hormone ablation in men with prostate cancer. It is also approved as Xgeva in the U.S. and EU to prevent skeletal related events in adults with bone metastases.
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) RBC Capital...

Read the full 773 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >